Wizja IOZK: wdrażanie wyników badań immunoonkologicznych w praktyce w odpowiednim czasie
Dr Wilfried Stücker jest dyrektorem zarządzającym IOZK i Fundacji IOZK. W 1985 roku zainicjował powstanie dzisiejszego Centrum Immunoonkologii w Kolonii. We współpracy z różnymi lekarzami i naukowcami opracował immunoterapię IOZK i założył centrum leczenia wraz z laboratoriami.
Fundacja IOZK została założona w 2019 r. w celu optymalizacji immunoterapii przeciwnowotworowych.
"Przedłużanie życia pacjentów chorych na raka i oferowanie im łagodnego leczenia jest tym, do czego jesteśmy zobowiązani w IOZK dzięki naszej wiedzy specjalistycznej".
Dr Wilfried Stücker
Kolekcja: Wkład naukowy i międzynarodowe publikacje dr Wilfrieda Stückera
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-06-23 / Biomedicines 2023 Jun;11(7)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-06-23 / Biomedicines 2023 Jun;11(7)2023-06-23 00:00:002024-04-17 15:04:06The Application of Evidence-Based Medicine in Individualized Medicine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-02-13 / Cancers (Basel) 2023 Feb;15(4)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002022-02-28 / Biomedicines 2022 Feb;10(3)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2022-02-28 / Biomedicines 2022 Feb;10(3)2022-06-02 00:00:002025-03-27 05:35:20Posterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002021-07-04 / Cancer Immunol Immunother 2021 Jul;https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2021-07-04 / Cancer Immunol Immunother 2021 Jul;2021-07-04 00:00:002021-11-15 12:29:15Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-05-19 / Medicines (Basel) 2020 May;7(5)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-08-30 / Biomedicines 2019 Aug;7(3)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-08-30 / Biomedicines 2019 Aug;7(3)2019-08-30 00:00:002021-11-15 13:22:59Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002015-05-28 / Immunotherapy 2015;7(8):855-60https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-24062014-10-06 00:00:002021-11-16 07:53:33Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
The Complexity of Malignant Glioma Treatment
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Prezentacja plakatu na dorocznym spotkaniu Stowarzyszenia Immunoterapii Nowotworów
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report